Quick answer: CJC-1295 is a synthetic analog of growth hormone releasing hormone, or GHRH, modified so that enzymes in the blood degrade it more slowly than they degrade the natural hormone. Two different compounds circulate under the same name: one carries a drug affinity complex, abbreviated DAC, and remains active in the body for days, while the version without DAC clears in well under an hour. Published human work on CJC-1295 is limited to small early-phase pharmacology studies that measured growth hormone and IGF-1 concentrations in blood, not long-term health outcomes. CJC-1295 has no FDA-approved indication in the United States and is prohibited in tested sport.
CJC-1295 belongs to the family of compounds known as growth hormone secretagogues, molecules that prompt the pituitary to release growth hormone rather than supplying growth hormone from outside the body. Within that family, CJC-1295 is a GHRH analog, meaning it binds the same pituitary receptor the body's own GHRH binds. The engineering question CJC-1295 was built to answer was not potency but duration.
What CJC-1295 is at the molecular level
CJC-1295 is a modified fragment of GHRH, built on the first twenty-nine amino acids of the natural hormone, the same active region that sermorelin is based on. Four amino acid substitutions in that chain make the molecule resistant to dipeptidyl peptidase-4, the enzyme that clips native GHRH apart within minutes of release. Slowing that first degradation step is the entire design premise.
Native GHRH has a circulating half-life of a few minutes, appropriate for a signal the hypothalamus sends in short bursts. Substituting the vulnerable residues extends that window without changing which receptor the molecule occupies. CJC-1295 is therefore not a new mechanism, but the familiar GHRH mechanism held open longer.
DAC and no-DAC are two different compounds sharing one name
The drug affinity complex is the single largest source of confusion around CJC-1295. DAC is a maleimide group attached to the peptide that lets it bind covalently to circulating albumin, and albumin turns over slowly, so the bound peptide is carried in the bloodstream for days rather than minutes. Early pharmacology reported a terminal half-life on the order of a week for the DAC version.
The version sold without DAC is chemically the modified GHRH fragment on its own, with no albumin anchor. Duration for that version is measured in minutes, which makes its behavior far closer to sermorelin than to the DAC-bearing molecule. Two products labeled CJC-1295 can therefore have pharmacokinetics that differ by three orders of magnitude, which is a meaningful problem when reading any secondhand account of what CJC-1295 does.
Why longer duration is a tradeoff rather than an upgrade
Growth hormone is not released as a steady stream in healthy physiology. Release occurs in discrete pulses, mostly during slow-wave sleep, separated by intervals in which levels fall close to undetectable. The trough appears to matter as much as the peak, because target tissues resensitize during it.
A compound that keeps GHRH receptor stimulation elevated for days changes that pattern by raising the baseline between pulses rather than sharpening the pulses themselves. Some clinicians read that as a departure from normal physiology rather than an improvement on it, and prefer shorter-acting agents specifically because they permit the signal to fall away again. Whether the flattened pattern carries any consequence over long periods in healthy adults has not been established in published human trials.
Readers weighing this specific question against a shorter-acting GHRH analog will find the pharmacokinetic contrast laid out in the side-by-side comparison of sermorelin and CJC-1295.
What the human evidence actually shows
Human data on CJC-1295 consists of a small number of early-phase pharmacology studies in healthy volunteers, published roughly two decades ago, involving tens of participants rather than hundreds. Those studies did what phase one studies are designed to do: they measured how the compound behaves in the body and what happens to circulating hormone concentrations. Growth hormone and IGF-1 rose, and the rise persisted for days with the DAC version.
Moving a lab value is not the same as demonstrating a clinical benefit, and the distinction is the whole point of reading this literature carefully. Nothing in that early work tested whether higher IGF-1 produced better sleep, better recovery, changed body composition, or altered any outcome a person would notice. No randomized trial has since tested those endpoints for CJC-1295 in healthy adults.
The habit of separating a measured biomarker from a demonstrated outcome is worth carrying into every compound in this category, and the method is set out in the guide to reading peptide evidence.
Regulatory status and status in tested sport
CJC-1295 has never been approved by the FDA for any indication, and development was not carried through to registration. Compounded preparations are not FDA-approved and are not equivalent to an approved drug, a point that applies across this whole category.
The World Anti-Doping Agency prohibits growth hormone secretagogues, including GHRH analogs, at all times both in and out of competition. Any athlete subject to testing should regard CJC-1295 as prohibited without needing to check the specific product name. Legal status for possession is a distinct question from approval status, covered separately in the overview of peptide legality in the United States.
Where CJC-1295 sits among the other secretagogues
Within the secretagogue landscape, CJC-1295 is best understood as one axis of variation: same receptor as other GHRH analogs, longer duration. A second axis runs through an entirely different receptor, the ghrelin receptor, which is where ipamorelin acts. A third distinction is regulatory rather than pharmacological, and tesamorelin is the compound that illustrates it, being the one GHRH analog with a genuine FDA approval behind it.
Placing a compound on those three axes is more useful than ranking secretagogues against one another. Duration, receptor, and depth of evidence are separable properties, and a compound can be unusual on one while ordinary on the others.
Frequently Asked Questions
Is CJC-1295 the same as sermorelin?
CJC-1295 and sermorelin are both GHRH analogs acting at the same pituitary receptor, so the mechanism is shared. The difference is duration, since sermorelin clears within minutes and CJC-1295 with DAC persists for days. A full comparison is available in the sermorelin and CJC-1295 breakdown.
What does DAC mean in CJC-1295 with DAC?
DAC stands for drug affinity complex, a chemical group that binds the peptide to albumin in the bloodstream. Albumin circulates for weeks, so the attached peptide is protected from rapid clearance. Without DAC, the same peptide is cleared quickly and behaves very differently.
Does CJC-1295 have FDA approval?
CJC-1295 has no FDA-approved indication in the United States. Development did not proceed to registration, and no product carrying that name is an approved drug. Compounded preparations are not FDA-approved and are not a substitute for approved products.
Is CJC-1295 permitted in tested sport?
CJC-1295 is prohibited under World Anti-Doping Agency rules, which ban growth hormone secretagogues and GHRH analogs at all times. Athletes subject to testing should assume any compound in this class will trigger a violation. Testing bodies do not require a compound to be approved for it to be prohibited.
Why is CJC-1295 often paired with a ghrelin receptor agonist?
Pairing a GHRH analog with a ghrelin receptor agonist targets two separate receptors that both influence pituitary release, which in short pharmacology studies produced larger hormone rises than either alone. Whether that larger biochemical response translates into any difference a person would notice has not been demonstrated in controlled human trials. The rationale is mechanistic rather than outcome-based.
Does a rise in IGF-1 mean CJC-1295 is working?
A rise in IGF-1 confirms the compound is engaging its receptor and that the pituitary is responding, which is a pharmacological finding rather than a clinical one. Outcomes such as sleep quality, recovery, or body composition were not endpoints in the published human work. Confirming a signal reached its target is a lower bar than showing the signal helped.
The honest summary
CJC-1295 is a well-characterized piece of chemistry attached to a thin evidence base. The molecular design is clear, the pharmacokinetics of both versions are documented, and the mechanism is not in dispute. What is missing is the layer that matters most, which is controlled human evidence that the biochemical change produces a benefit worth having.
Anyone reading about this compound should hold two facts side by side: the DAC and no-DAC versions are not the same drug, and neither has outcome data in healthy adults. Broader context on how these molecules are classified is available in the introduction to peptides. Decisions about any prescription therapy belong with a licensed clinician who can evaluate an individual case.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 2006. PMID 16352683.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology. 2026. PMID 42395176.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.